INCREASELUNGGROWTH08

Impact of surgical and pharmacological interventions on fetal lung growth in pulmonary hypoplasia

Coordinatore	Medizinische Universitaet Graz    more  Organization address address: AUENBRUGGERPLATZ 2 city: GRAZ postcode: 8036 contact info Titolo: Dr. Nome: Carolin Cognome: Auer Email: send email Telefono: -72674 Fax: +43 316 385-72030
Nazionalità Coordinatore	Austria [AT]
Totale costo	45˙000 €
EC contributo	45˙000 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-ERG-2008
Funding Scheme	MC-ERG
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-12-15   -   2012-12-14

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	Medizinische Universitaet Graz  Organization address address: AUENBRUGGERPLATZ 2 city: GRAZ postcode: 8036 contact info Titolo: Dr. Nome: Carolin Cognome: Auer Email: send email Telefono: -72674 Fax: +43 316 385-72030	AT (GRAZ)	coordinator	45˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Pulmonary hypoplasia is a significant cause of perinatal death and occurs with an incidence of 15%. A common (1:2500 newborns) malformation resulting in hypoplastic lungs is congenital diaphragmatic hernia (CDH). Affected lungs have reduced and functionally altered airways and vessels, leading to respiratory deficiency and pulmonary hypertension in the neonatal period. Nowadays, prenatal fetoscopic endoluminal tracheal occlusion (FETO) can be offered in selected cases to prevent excess of pulmonary fluid and thus triggering lung growth. However, the procedure remains invasive with the main risk of premature rupture of the membranes and still 40% of affected neonates succumb, the majority due to persistent hypoplasia. Therefore, pharmacological agents, including vitamins, hyperoncotic agents and growth factors, have been proposed as an additional prenatal treatment approach to further improve postnatal outcome. Experimental section: We aim to investigate the potential of two important growth factors, VEGF and IGF-1, to stimulate lung growth in the nitrofen rat model for pulmonary hypoplasia, with particular interest on dosage, route and time-point of administration. If beneficial, the obtained results will provide a profound scientific basis for a pharmacological treatment modality that can be applied by fetoscopy or even via ultrasound-guided needle procedures in fetuses affected by CDH. Clinical section: Few centers, including the former host institution, offer FETO and termination of affected pregnancies is still widely performed. We plan to perform advanced clinical evaluation of afflicted pregnancies in the framework of a specialized outpatient clinic in Graz, Austria, in close collaboration with the former host institution in Leuven, Belgium, with regards to transfer of patients and data. Advancing the national awareness for prenatal therapeutic options will complete our intentions to improve postnatal survival and morbidity in babies affected by CDH.'